Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Serina Therapeutics (SER) Gross Margin (2018 - 2023)

Historic Gross Margin for Serina Therapeutics (SER) over the last 6 years, with Q4 2023 value amounting to 1.78%.

  • Serina Therapeutics' Gross Margin fell 857200.0% to 1.78% in Q4 2023 from the same period last year, while for Dec 2023 it was 3.24%, marking a year-over-year decrease of 585300.0%. This contributed to the annual value of 3.24% for FY2023, which is 585300.0% down from last year.
  • Serina Therapeutics' Gross Margin amounted to 1.78% in Q4 2023, which was down 857200.0% from 117.24% recorded in Q3 2023.
  • Over the past 5 years, Serina Therapeutics' Gross Margin peaked at 117.24% during Q3 2023, and registered a low of 1.78% during Q4 2023.
  • Its 5-year average for Gross Margin is 76.17%, with a median of 85.83% in 2019.
  • Examining YoY changes over the last 5 years, Serina Therapeutics' Gross Margin showed a top increase of 728000bps in 2023 and a maximum decrease of -857200bps in 2023.
  • Serina Therapeutics' Gross Margin (Quarter) stood at 85.61% in 2019, then increased by 13bps to 96.84% in 2020, then decreased by -1bps to 96.3% in 2021, then dropped by -9bps to 87.5% in 2022, then crashed by -98bps to 1.78% in 2023.
  • Its Gross Margin was 1.78% in Q4 2023, compared to 117.24% in Q3 2023 and 57.14% in Q2 2023.